Business
Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today
Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information
About this update from Alvotech
[{"type":"text","content":"Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — On May 16, 2025 Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the outcome of the offering of Swedish Depository Receipts (“SDRs”), equity share equivalents, in connection with the Company’s listing on Nasdaq Stockholm (the “Offering”). The Offering attracted strong interest from the general public in Sweden and was multiple times oversubscribed. Trading on Nasdaq Stockholm commences today May 19, 2025. The Offering in brief As previously announced, the final price per SDR (the “Offering Price”) was set to SEK 87.51, corresponding to the volume-weighted average price of the ordinary shares of the Company (the “Shares”) on the Nasdaq Iceland Main Market during the application period, with a discount of ten percent (10%), converted from ISK to SEK based on the exchange rate published by the Swedish Central Bank (Sw. Sveriges Riksbank) on the last day of the application period. The application period was May 9–16, 2025.The Offering included 441,600 SDRs, with each SDR representing one ordinary share of the Company. The Offering was multiple times oversubscribed.The gross proceeds of the Offering amounted to approximately SEK 39 million.All of the more than 3,000 individuals who subscribed to acquire SDRs in the Offering were allotted SDRs.Trading in the Company’s SDRs on Nasdaq Stockholm commences today, May 19, 2025, under the trading symbol (ticker) “ALVO SDB”.Settlement is expected to take place on May 21, 2025. “Alvotech’s goal is to become the global leader in biosimilars development and manufacturing, providing better access to high-quality biologics for patients globally in 90 different countries, through our commercial partnerships. Today marks the next exciting step in Alvotech’s journey as the Company is listed on Nasdaq Stockholm. Alvotech’s shares are now traded on three markets; Nasdaq Stockholm in Sweden, Nasdaq Global Market in the U.S. and Nasdaq Iceland Main Market in Iceland. W...